Australia's Clarity Pharma hits record high on upbeat revenue, trial progression

Clarity Pharmaceuticals

23/08/2024 02:27

** Shares of Clarity Pharmaceuticals  CU6.AX  rise as much
as 5.2% to a record high of A$7.25
    ** Co logs 49% increase in FY24 revenue from ordinary
activities to A$2.8 million ($1.88 million)
    ** Analysts at Bell Potter expect strong interest from U.S.
investigators and Food and Drug Administration for co's trial to
treat biochemical recurrence of prostate cancer
    ** The assets in clinical stage development by CU6 continue
to show outstanding safety with good indications of efficacy
supported by composition of matter patents - Bell Potter  
    ** Shares log three-straight days of gains 
    ** Stock up 263.8% this year as of last close
    
($1 = 1.4901 Australian dollars)

 (Reporting by Roushni Nair in Bengaluru)
 ((Roushni.Nair@thomsonreuters.com;))